Please assess the completion status of the following clinical trial:

Trial Title: Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subject has received mechanical ventilation for at least 48h at the time of the randomisation OR at least 2 of the following signs or symptoms presenting within 24 hours prior to randomization: New onset of cough or worsening of baseline cough and/or dyspnea, tachypnea and/or hypoxemia and/or new onset of sputum or suctioned respiratory secretion characterized by purulent appearance indicative of bacterial infection or a worsening in character of purulent appearance~* Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 25, inclusive, within 24h prior to randomization~* Presence of new or progressive infiltrate on chest X-ray~* Presence of clinical criteria consistent with Pneumonia~* Strong clinical suspicion of pneumonia due to P. aeruginosa~Key Exclusion Criteria:~* Known or suspected community-acquired bacterial pneumonia or viral, fungal, or parasitic pneumonia~* known hypersensitivity to any component of ertapenem, meropenem or to other drugs in the same class or demonstrated anaphylactic reactions to beta-lactams or a history of allergic reactions to any of the penicillins, cephalosporins, or β-lactamase inhibitors~* Severe liver or renal impairment~* Expected survival \< 72 hours~* Evidence from an available surveillance culture of co infection with ertapenem , meropenem or piperacillin tazobactam resistant Gram negative pathogen(s)~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Murepavadin (Type: EXPERIMENTAL): Murepavadin + ertapenem
- Anti-pseudomonal antibiotic (Type: ACTIVE_COMPARATOR): One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)

Based on this trial design, predict the completion outcome and termination type (if applicable).